Director of the Board
Lene Andersen (Danish, born 1958) joined PILA PHARMA in 2016 as Director of the Board due to her thorough understanding of the diabetes market, its growth drivers and positioning of new diabetes drugs.
Lene Andersen holds a BA in Economics from Copenhagen Business School, Denmark from 1989 as well as an MSc in Sustainability and Responsibility from Ashridge Business School in London, United Kingdom from 2012. As an independent consultant she helps start-up companies and is an active member of Keyhaven Capital Partners.
Lene Andersen provides significant experience to PILA PHARMA within licensing, business strategy & development and project management in the diabetes field obtained through senior operational leadership roles in Operations and Corporate Relations during her almost 2 decades at Novo Nordisk, a Danish healthcare company in the diabetes segment. Besides, she brings a comprehensive toolbox from her consultancy role where she helps companies succeed with their strategi realisation, leadership and organisational development.
Lene Andersen worked with licensing and business development (1994-2000) after which she in 2001-02 was heading New Product Planning in diabetes where she ensured integration of business needs into global development projects. She was promoted to Project and Corporate Vice President for the development and marketing of the modern insulin portfolio in 2006-2008 and developed a winning portfolio strategy for the modern insulins. During that period, 65% of the growth of the company was attributable to the modern insulin portfolio. In 2008-2012, she was Vice President in Corporate Relations in charge of the global patient strategy and execution of external partnerships within diabetes.
Currently Lene is partner in Genux Executive, specialised in leadership, business coaching, recruitment and assessment.